BiondVax Announces Closing of $8 Million Underwritten Public Offering

JERUSALEM, Dec. 20, 2022 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV)('Company'), a biotechnology company, which focuses on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, today announced the closing of its underwritten public offering with gross proceeds to the Company to be $8,000,000, before deducting underwriting discounts and other expenses payable by the Company.

The offering consists of 1,600,000 units and pre-funded units. Each unit consists of one American Depositary Share ('ADS') and two warrants, each to purchase one ADS, and each pre-funded unit consists of one pre-funded warrant to purchase one ADS and two warrants each to purchase one ADS. One of the warrants will expire three years from the date of issuance, and the other warrant will expire one year from the date of issuance and may be exercised for half an ADS on or prior to six (6) months following the original issuance for no additional consideration.

Each ADS (or pre-funded warrant) is being sold together with two warrants at a combined purchase price of $5.00 per unit (or $4.999 per pre-funded unit after reducing $0.001 attributable to the exercise price of the pre-funded warrants). Each ADS represents 400 of our ordinary shares, no par value per share. The Company expects to use the net proceeds from the offering, together with its existing cash and cash equivalents, for the advancement of its NanoAbs development program, as well as general corporate purposes, which may include working capital, research and development activities, regulatory matters, capital investment or other related purposes.

Aegis Capital Corp. acted as the sole book-running manager for the offering. A registration statement on Form F-1 (File No. 333-267648) relating to the offering of the securities has been filed with the U.S.

Securities and Exchange Commission (SEC) and declared effective by the SEC on December 15, 2022. The offering is being made only by means of a prospectus, copies of which may be obtained by contacting Aegis Capital Corp., 1345 Avenue of the Americas, 27th Floor, New York, NY 10105, by telephone at (212) 813-1010 or by email at EMAIL. Copies of the registration statement can be accessed through the SEC's website at URL.

This press release does not constitute an offer or solicitation to buy securities. Nor shall it be sold in any state or territory in which such an offer, solicitation, or sale would be illegal prior to registration under the securities laws. BiondVax Pharmaceuticals Ltd., Nasdaq: BVXV, is a biotechnology firm that develops, manufactures, and markets innovative immunotherapeutic drugs primarily for the treatment and prevention of infectious and autoimmune disease.
.

The company has conducted eight clinical trials since its inception. This includes a Phase 3 trial with a prior vaccine candidate that involved 12,400 participants and seven countries. It has also built a state of the art manufacturing facility for biopharmaceutical product development. BiondVax has a highly skilled pharmaceutical industry leader and is working to build a portfolio of commercially viable products. Its first product is an innovative nanosized antibody pipeline (NanoAb). URL
.

Email__ Forward-Looking statements This press release contains forward looking statements as defined by the Private Litigation Reform Act (1996). Forward-looking statements are identified by words such as "expect", "believe,"" "intend,","plan,"continue," may," will," anticipate, and similar expressions. Forward-looking statements include all statements other than historical facts regarding strategy, future operations and financial position, future revenue, projected expenditures, prospects, plans, objectives, and management.
.

These statements may include statements about the closing date, the anticipated use of proceeds from this offering, the timing and location of future clinical trials and the therapeutic and commercial potential for NanoAbs. These forward-looking statements are based on management's current views regarding certain events. They are subject to a variety of risks, uncertainties, assumptions, and risks that could cause results to differ from what was expected.
.

More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in the Company's Annual Report on Form 20-F filed with the Securities and Exchange Commission on March 28, 2022. BiondVax undertakes no obligation to revise or update any forward-looking statement for any reason. Corporate Communications:InvestorBrandNetwork (IBN) Los Angeles, California URL 310.299.1717 Office EMAIL